CRESCENT BIOPHARMA, INC. annual report, FY2014

Business context and reporting period

This is GlycoMimetics, Inc.’s Form 10-K for the fiscal year ended December 31, 2014, filed March 16, 2015. The request metadata names Crescent Biopharma, but the filing identifies GlycoMimetics (NASDAQ: GLYC). The company is a clinical-stage biotechnology developer of glycomimetic drug candidates; it had no products for sale.

Financial performance and position

FY 2014 revenue primarily reflects a non-refundable $15.0 million Pfizer milestone payment; there was no product-sale revenue. The company ended 2014 with $55.2 million cash and cash equivalents, $57.3 million total assets, $6.5 million total liabilities, and $50.8 million stockholders’ equity. No borrowings are reported on the balance sheet. Current assets were $56.1 million versus current liabilities of $6.5 million. Operating cash flow benefited from the Pfizer payment and changes in accrued liabilities; it should not be read as a recurring cash-burn rate. Lease commitments totaled $5.7 million.

Material changes versus the prior year

• Revenue rose $11.0 million, primarily due to Pfizer’s milestone payment; the remaining $20.0 million of the first Phase 3 milestone is contingent on first-patient dosing.
• R&D expense increased $7.9 million, mainly from GMI-1271 manufacturing and process development. GMI-1271 accounted for $9.6 million of 2014 R&D spending.
• G&A expense increased $3.7 million, largely from public-company costs, professional fees, insurance, and stock-based compensation.
• Cash increased from $2.3 million at year-end 2013, reflecting $57.2 million of IPO net proceeds and the Pfizer milestone, partly offset by operating and investing outflows.
• Weighted-average shares rose substantially following the January 2014 IPO and conversion of preferred stock; year-over-year per-share comparisons are affected by this change.

Outlook, commentary, and key risks

• Management expected year-end cash to fund operations and capital expenditures into the second half of 2016, excluding potential Pfizer milestones. The estimate depends on assumptions; additional financing may be needed and is not committed.
• Pfizer assumed further development and commercialization of rivipansel. It reported a significant Phase 3 delay due to a manufacturing issue affecting formulated drug supply. The timing and resolution were uncertain at filing.
• Rivipansel’s Phase 2 study showed favorable directional changes in crisis resolution, hospital discharge, and opioid use, but the primary endpoint was not statistically significant. Opioid use was reduced 83% with p=0.01; safety events were generally comparable between groups.
• GMI-1271 completed a single-dose Phase 1 trial in 28 healthy volunteers and was reported as well tolerated. Patient recruitment for a Phase 1/2 AML study was anticipated to begin in Q1 2015; efficacy remained unproven.
• The company also described GMI-1359, GMI-1051, and galectin programs as preclinical. Development, regulatory approval, manufacturing, competition, reimbursement, intellectual-property protection, and reliance on third parties are material risks.
• 2014 Q4 revenue was zero and net loss was $7.4 million. The $8.0 million Q2 net income reflected the Pfizer milestone, not recurring product sales. The company reported no material legal proceedings and no off-balance-sheet arrangements.

Important facts for investors to verify

1. Whether Pfizer resolves the formulated-drug manufacturing issue, starts the rivipansel Phase 3 trial, and triggers the remaining $20.0 million milestone.
2. Whether the reported cash runway remains achievable as clinical-trial costs rise, and the timing and terms of any additional financing.
3. The complete Phase 2 rivipansel results and statistical analysis, particularly the nonsignificant primary endpoint and the reported opioid-use reduction.
4. GMI-1271 trial initiation, enrollment, safety, and subsequent efficacy data; current conclusions are based on early-stage and preclinical evidence.
5. Potential share dilution, including outstanding equity awards and future financing, and the 10% share of future rivipansel milestone and royalty receipts payable to the University of Basel.